{"id":8840,"date":"2025-06-26T06:16:52","date_gmt":"2025-06-26T11:16:52","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=8840"},"modified":"2025-07-13T15:08:42","modified_gmt":"2025-07-13T20:08:42","slug":"nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u65b0\u305f\u306a\u5148\u898b\u6027\u306e\u3042\u308b\u8aee\u554f\u59d4\u54e1\u4f1a\u3068\u5171\u306b\u3001\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u306b\u304a\u3051\u308b\u60a3\u8005\u4e2d\u5fc3\u306e\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u63a8\u9032"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"8840\" class=\"elementor elementor-8840\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-65279c3f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"65279c3f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4b40c268\" data-id=\"4b40c268\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-76485331 elementor-widget elementor-widget-text-editor\" data-id=\"76485331\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"col-sm-8 col-vcenter col-xs-12\"><div class=\"col-sm-8 col-vcenter col-xs-12\"><div class=\"col-sm-8 col-vcenter col-xs-12\"><div class=\"col-sm-8 col-vcenter col-xs-12\"><div class=\"col-sm-8 col-vcenter col-xs-12\"><h3 style=\"text-align: center;\">\u00a0<\/h3><\/div><div class=\"col-sm-4 col-xs-12 col-vcenter\"><div class=\"image logo logo-wrapper\" data-src=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-asset-type=\"photo\" data-asset-label=\"Logo\" data-download-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg\" data-tweet-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-pinterest-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-linkedin-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-facebook-share-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-twitter-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=twitter\" data-facebook-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=facebook\" data-pinterest-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-linkedin-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=linkedin\"><p><span class=\"legendSpanClass\"><span class=\"xn-location\">\u30c0\u30e9\u30b9<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">2025\u5e746\u670826\u65e5 <\/span><\/span>\u2014\u00a0<a href=\"http:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>, \u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u306b\u82e6\u3057\u3080\u60a3\u8005\u306e\u305f\u3081\u306e\u65b0\u898f\u907a\u4f1d\u5b50\u975e\u4f9d\u5b58\u578b\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u3068\u5546\u696d\u5316\u306b\u53d6\u308a\u7d44\u3080\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b \u306f\u672c\u65e5\u3001\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/who-we-are\/#vac\" target=\"_blank\" rel=\"nofollow noopener\">\u30d3\u30b8\u30e7\u30ca\u30ea\u30fc\u8aee\u554f\u59d4\u54e1\u4f1a\uff08VAC\uff09<\/a>\u00a0\u2015\u7db2\u819c\u6cbb\u7642\u3068\u5546\u696d\u5316\u306b\u304a\u3051\u308b\u8457\u540d\u306a\u5c02\u9580\u5bb6\u30b0\u30eb\u30fc\u30d7\u3002.<\/p><p class=\"prntaj\">VAC\u306f\u3001\u6226\u7565\u7684\u304b\u3064\u30df\u30c3\u30b7\u30e7\u30f3\u306b\u6cbf\u3063\u305f\u30c1\u30fc\u30e0\u3068\u3057\u3066\u6a5f\u80fd\u3057\u3001Nanoscope\u306e\u79d1\u5b66\u7684\u3001\u81e8\u5e8a\u7684\u3001\u304a\u3088\u3073\u5730\u57df\u793e\u4f1a\u306b\u5411\u3051\u305f\u53d6\u308a\u7d44\u307f\u306b\u60c5\u5831\u3092\u63d0\u4f9b\u3059\u308b\u3002.\u00a0<b><i>\u305d\u306e\u4f7f\u547d\u306f\u3001\u60a3\u8005\u30b1\u30a2\u3092\u5411\u4e0a\u3055\u305b\u3001\u533b\u5e2b\u3068\u306e\u771f\u646f\u306a\u95a2\u308f\u308a\u3092\u4fc3\u9032\u3057\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u304a\u3088\u3073\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\u3092\u60a3\u3046\u4eba\u3005\u306b\u9769\u65b0\u7684\u306a\u6cbb\u7642\u6cd5\u3092\u6700\u521d\u306b\u63d0\u4f9b\u3059\u308b\u305f\u3081\u306e\u9053\u7b4b\u3092\u63cf\u304f\u3053\u3068\u3067\u3059\u3002.<\/i><\/b><\/p><p class=\"prntaj\">\u201c\u300c\u3053\u308c\u306f\u5358\u306a\u308b\u59d4\u54e1\u4f1a\u4ee5\u4e0a\u306e\u3082\u306e\u3067\u3059\u3002\u79c1\u305f\u3061\u304c\u5949\u4ed5\u3059\u308b\u60a3\u8005\u3068\u79c1\u305f\u3061\u304c\u4fe1\u3058\u308b\u4f7f\u547d\u306b\u5bfe\u3059\u308b\u63fa\u308b\u304e\u306a\u3044\u30b3\u30df\u30c3\u30c8\u30e1\u30f3\u30c8\u3092\u660e\u78ba\u306b\u8868\u660e\u3059\u308b\u3082\u306e\u3067\u3059\u300d\u3068\u8ff0\u3079\u305f\u3002\u00a0<span class=\"xn-person\">\u30b9\u30e9\u30cb\u30e3\u30fb\u30d0\u30bf\u30c1\u30e3\u30ea\u30e4<\/span>, \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306e\u5171\u540c\u5275\u696d\u8005\u517cCEO\u306f\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u3067\u306f\u3001\u79c1\u305f\u3061\u304c\u652f\u63f4\u306b\u5c3d\u529b\u3059\u308b\u60a3\u8005\u3055\u3093\u306e\u751f\u6d3b\u3092\u771f\u306b\u7406\u89e3\u3057\u3066\u3044\u308b\u65b9\u3005\u306e\u6307\u5c0e\u306e\u3082\u3068\u3001\u5e38\u306b\u8996\u91ce\u3092\u5e83\u3052\u306a\u304c\u3089\u3001\u7db2\u819c\u75be\u60a3\u6cbb\u7642\u306e\u672a\u6765\u3092\u7bc9\u3044\u3066\u3044\u307e\u3059\u3002\u300d\u201c<\/p><p class=\"prntaj\">MCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306b\u5bfe\u3059\u308b\u958b\u767a\u4e2d\u306e\u81e8\u5e8a\u6bb5\u968e\u306b\u3042\u308b\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u306e\u4e2d\u3067\u6700\u3082\u5148\u9032\u7684\u306a\u3082\u306e\u3067\u3059\u3002\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u72ec\u81ea\u306e\u591a\u7279\u6027\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u3092\u7528\u3044\u305fMCO-010\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u4f4e\u4e0b\u60a3\u8005\u306b\u5bfe\u3059\u308b\u8996\u529b\u56de\u5fa9\u306e\u53ef\u80fd\u6027\u3092\u793a\u3057\u305f\u521d\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u9a13\u85ac\u3067\u3059\u3002.<\/p><p class=\"prntaj\">\u201c\u300cMCO-010\u306e\u7279\u5fb4\u306f\u3001\u79d1\u5b66\u7684\u306a\u9032\u6b69\u3060\u3051\u3067\u306a\u304f\u3001\u5b9f\u7528\u6027\u306e\u9ad8\u3055\u306b\u3082\u3042\u308a\u307e\u3059\u300d\u3068\u30d0\u30c3\u30bf\u30c1\u30e3\u30ea\u30e4\u6c0f\u306f\u4ed8\u3051\u52a0\u3048\u305f\u3002\u300c\u907a\u4f1d\u5b50\u691c\u67fb\u3084\u624b\u8853\u3001\u7d99\u7d9a\u7684\u306a\u30e1\u30f3\u30c6\u30ca\u30f3\u30b9\u3092\u5fc5\u8981\u3068\u305b\u305a\u3001\u8a3a\u7642\u6240\u30671\u56de\u306e\u6ce8\u5c04\u3067\u6295\u4e0e\u3067\u304d\u308b\u3088\u3046\u306b\u8a2d\u8a08\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u300d\u201d<\/p><p>\u306e\u00a0<b>VAC\u306e\u8b70\u9577\u306f\u3001\u30de\u30cd\u30fc\u30b8\u30f3\u30b0\u30c7\u30a3\u30ec\u30af\u30bf\u30fc\u306eSriniVas Sadda\u6c0f\u304c\u52d9\u3081\u308b\u3002<\/b>.\u3001A\u3002.\u00a0<span class=\"xn-person\">\u30ec\u30a4\u30fb\u30a2\u30fc\u30d0\u30a4\u30f3\u30fb\u30b8\u30e5\u30cb\u30a2.<\/span>, \u533b\u5b66\u535a\u58eb\u3001\u81e8\u5e8a\u773c\u79d1\u5b66\u306e\u5bc4\u4ed8\u8b1b\u5ea7\u6559\u6388\u3001\u00a0<span class=\"xn-org\">\u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5927\u5b66\u30ed\u30b5\u30f3\u30bc\u30eb\u30b9\u6821<\/span>\u00a0\u30c7\u30d3\u30c3\u30c9\u30fb\u30b2\u30d5\u30a3\u30f3\u533b\u79d1\u5927\u5b66\u304a\u3088\u3073\u30c9\u30d8\u30cb\u30fc\u773c\u79d1\u7814\u7a76\u6240\u3002.<\/p><p class=\"prntaj\">\u201c\u300c\u7db2\u819c\u5c02\u9580\u533b\u3068\u3057\u3066\u3001\u79c1\u305f\u3061\u306f\u60a3\u8005\u3055\u3093\u3068\u306e\u5931\u660e\u306b\u95a2\u3059\u308b\u4f1a\u8a71\u3092\u3001\u907f\u3051\u3089\u308c\u306a\u3044\u3082\u306e\u304b\u3089\u53ef\u80fd\u6027\u3078\u3068\u5909\u3048\u308b\u3068\u3044\u3046\u5207\u5b9f\u306a\u5fc5\u8981\u6027\u306b\u76f4\u9762\u3057\u3066\u3044\u307e\u3059\u300d\u3068\u30b5\u30c3\u30c0\u533b\u5e2b\u306f\u8ff0\u3079\u307e\u3057\u305f\u3002\u300c\u73fe\u72b6\u7dad\u6301\u306f\u7d76\u5bfe\u7684\u306a\u3082\u306e\u3067\u306f\u306a\u304f\u3001\u8996\u529b\u56de\u5fa9\u306f\u5922\u3067\u306f\u306a\u304f\u3001\u624b\u306e\u5c4a\u304f\u76ee\u6a19\u3067\u3042\u308b\u3068\u4fe1\u3058\u308b\u30c1\u30fc\u30e0\u306e\u4e00\u54e1\u3067\u3042\u308b\u3053\u3068\u3092\u5149\u6804\u306b\u601d\u3044\u307e\u3059\u3002\u300d\u201d<\/p><p>\u30b5\u30c3\u30c0\u535a\u58eb\u306e\u4ed6\u306b\u3001VAC\u306e\u30e1\u30f3\u30d0\u30fc\u306b\u306f\u4ee5\u4e0b\u306e\u4eba\u7269\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p><ul type=\"disc\"><li><b><span class=\"xn-person\">\u30a2\u30ec\u30f3\u30fb\u30db\u30fc<\/span>\u533b\u5b66\u535a\u58eb\u3001\u00a0<\/b>\u773c\u79d1\u5b66\u6559\u6388,\u00a0<span class=\"xn-org\">\u30c8\u30fc\u30de\u30b9\u30fb\u30b8\u30a7\u30d5\u30a1\u30fc\u30bd\u30f3\u5927\u5b66<\/span>\u00a0\u30a6\u30a3\u30eb\u30ba\u773c\u79d1\u75c5\u9662\u7db2\u819c\u7814\u7a76\u90e8\u9577\u3002\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306e\u6700\u9ad8\u533b\u7642\u9867\u554f\u3002<\/li><li><b><span class=\"xn-person\">\u30d4\u30fc\u30bf\u30fc\u30fb\u30ab\u30a4\u30b6\u30fc<\/span>\u533b\u5b66\u535a\u58eb\u3001\u00a0<\/b>\u30af\u30ea\u30fc\u30d6\u30e9\u30f3\u30c9\u30fb\u30af\u30ea\u30cb\u30c3\u30af\u30fb\u30e9\u30fc\u30ca\u30fc\u533b\u79d1\u5927\u5b66\u773c\u79d1\u5b66\u6559\u6388\u3001\u30b3\u30fc\u30eb\u773c\u79d1\u7814\u7a76\u6240\u30c1\u30a7\u30a4\u30cb\u30fc\u5bb6\u5bc4\u4ed8\u8b1b\u5ea7\u773c\u79d1\u5b66\u7814\u7a76\u62c5\u5f53<\/li><li><b><span class=\"xn-person\">\u30af\u30ea\u30b9\u30c6\u30a3\u30f3\u30fb\u30b1\u30a4<\/span>, \u533b\u5b66\u535a\u58eb<\/b>.\u3001\u81e8\u5e8a\u7814\u7a76\u304a\u3088\u3073\u7db2\u819c\u907a\u4f1d\u5b66\u30c7\u30a3\u30ec\u30af\u30bf\u30fc\u3001\u785d\u5b50\u4f53\u7db2\u819c\u30a2\u30bd\u30b7\u30a8\u30a4\u30c4\u00a0<span class=\"xn-location\">\u30b2\u30a4\u30f3\u30ba\u30d3\u30eb<\/span><\/li><li><b><span class=\"xn-person\">\u30a2\u30eb\u30b7\u30e3\u30c9\u30fb\u30cf\u30ca\u30cb<\/span>, \u533b\u5b66\u535a\u58eb\u3001\u4fee\u58eb\u3001,\u00a0<\/b>\u81e8\u5e8a\u6559\u6388\u3001,\u00a0<span class=\"xn-org\">\u30cd\u30d0\u30c0\u5927\u5b66\u30ea\u30ce\u6821<\/span>\u00a0\u533b\u5b66\u90e8\u304a\u3088\u3073\u30b7\u30a8\u30e9\u30fb\u30a2\u30a4\u30fb\u30a2\u30bd\u30b7\u30a8\u30a4\u30c4\u81e8\u5e8a\u7814\u7a76\u90e8\u9577<\/li><li><b><span class=\"xn-person\">\u30f4\u30a3\u30cb\u30c3\u30c8\u30fb\u30de\u30cf\u30b8\u30e3\u30f3<\/span>, \u533b\u5b66\u535a\u58eb\u3001\u54f2\u5b66\u535a\u58eb,\u00a0<\/b>\u773c\u79d1\u5b66\u6559\u6388,\u00a0<span class=\"xn-org\">\u30b9\u30bf\u30f3\u30d5\u30a9\u30fc\u30c9\u5927\u5b66<\/span>\u00a0\u307e\u305f\u3001\u30d0\u30a4\u30a2\u30fc\u30ba\u773c\u79d1\u7814\u7a76\u6240\u306e\u7814\u7a76\u62c5\u5f53\u526f\u90e8\u9577\u517c\u5206\u5b50\u5916\u79d1\u30d7\u30ed\u30b0\u30e9\u30e0\u8cac\u4efb\u8005\u3082\u52d9\u3081\u308b\u3002<\/li><li><b>\u30b8\u30e7\u30eb\u30c7\u30a3\u30fb\u30e2\u30cd\u30b9\u533b\u5e2b\u3001\u533b\u5b66\u535a\u58eb\u3001,\u00a0<\/b>\u30de\u30ad\u30e5\u30e9\u7814\u7a76\u6240\u6240\u9577\u3001,\u00a0<span class=\"xn-location\">\u30d0\u30eb\u30bb\u30ed\u30ca<\/span><\/li><li><b><span class=\"xn-person\">\u30de\u30fc\u30af\u30fb\u30da\u30cd\u30b7<\/span>, \u533b\u5b66\u535a\u58eb\u3001\u54f2\u5b66\u535a\u58eb,\u00a0<\/b>\u30aa\u30ec\u30b4\u30f3\u5065\u5eb7\u79d1\u5b66\u5927\u5b66\u30b1\u30fc\u30b7\u30fc\u773c\u79d1\u7814\u7a76\u6240\u773c\u79d1\u5b66\u975e\u5e38\u52e4\u6559\u6388\u3001\u304a\u3088\u3073\u7db2\u819c\u8ca1\u56e3\u907a\u4f1d\u6027\u7db2\u819c\u5909\u6027\u90e8\u9580\u30c7\u30a3\u30ec\u30af\u30bf\u30fc<\/li><\/ul><p>\u8a73\u3057\u3044\u7d4c\u6b74\u306b\u3064\u3044\u3066\u306f\u3001\u4ee5\u4e0b\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/who-we-are\/#vac\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/nanostherapeutics.com\/who-we-are\/#vac<\/a><\/p><p class=\"prntaj\">VAC\u306e\u8a2d\u7acb\u306f\u3001\u60a3\u8005\u306b\u610f\u7fa9\u306e\u3042\u308b\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u3082\u305f\u3089\u3059\u3053\u3068\u306f\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u304b\u3089\u59cb\u307e\u308a\u3001\u884c\u52d5\u3078\u3068\u7d9a\u304f\u3068\u3044\u3046Nanoscope\u306e\u4fe1\u5ff5\u3092\u53cd\u6620\u3057\u305f\u3082\u306e\u3067\u3042\u308a\u3001\u7db2\u819c\u5909\u6027\u75c7\u306b\u82e6\u3057\u3080\u4e16\u754c\u4e2d\u306e\u4f55\u767e\u4e07\u4eba\u3082\u306e\u60a3\u8005\u306b\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059\u3053\u3068\u3092\u76ee\u6307\u3057\u3066\u3044\u307e\u3059\u3002.<\/p><p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u3067\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u308b\u3002RESTORE\u30d5\u30a7\u30fc\u30ba\u3067\u306e\u826f\u597d\u306a\u7d50\u679c\u3092\u53d7\u3051\u3066\u3001\u00a0<span class=\"xn-money\">2b<\/span>\/3 \u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306b\u5bfe\u3059\u308b\u591a\u65bd\u8a2d\u5171\u540c\u3001\u7121\u4f5c\u70ba\u5316\u3001\u4e8c\u91cd\u76f2\u691c\u3001\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>\uff09FDA\u3078\u306eBLA\u7533\u8acb\u306f\u9806\u6b21\u958b\u59cb\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3042\u308b\u3002\u00a0<span class=\"xn-chron\">2025\u5e746\u6708<\/span>. \u627f\u8a8d\u3055\u308c\u308c\u3070\u3001MCO-010\u306f\u907a\u4f1d\u5b50\u691c\u67fb\u3092\u5fc5\u8981\u3068\u305b\u305a\u3001\u8a3a\u7642\u6240\u30671\u56de\u6ce8\u5c04\u3059\u308b\u3060\u3051\u3067\u6295\u4e0e\u3067\u304d\u308b\u305f\u3081\u3001RP\u60a3\u8005\u306e\u6a19\u6e96\u6cbb\u7642\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u3002\u540c\u793e\u306f\u307e\u305f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\u306b\u5bfe\u3059\u308bMCO-010\u306e\u7b2c2\u76f8\u81e8\u5e8a\u8a66\u9a13STARLIGHT\u3067\u3082\u6709\u671b\u306a\u7d50\u679c\u3092\u793a\u3057\u3066\u3044\u308b\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\uff09\u305d\u3057\u3066\u3001\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30d5\u30a7\u30fc\u30ba3\u767b\u9332\u8a66\u9a13<\/a>\u00a02025\u5e74\u306b\u767a\u58f2\u4e88\u5b9a\u306eMCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3068\u810a\u9ac4\u6027\u7b4b\u840e\u7e2e\u75c7\uff08SD\uff09\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3068\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u306f\u3001IND\u7533\u8acb\u306b\u5411\u3051\u305f\u7814\u7a76\u6bb5\u968e\u306b\u3042\u308b\u30ec\u30fc\u30d0\u30fc\u5148\u5929\u6027\u9ed2\u5185\u969c\uff08LCA\uff09\u306e\u307b\u304b\u3001\u5730\u56f3\u72b6\u840e\u7e2e\u75c7\uff08GA\uff09\u306b\u5bfe\u3059\u308bIND\u7533\u8acb\u6e96\u5099\u6bb5\u968e\u306e\u85ac\u5264\u304c\u542b\u307e\u308c\u3066\u3044\u307e\u3059\u3002.<\/p><p><b>\u63a5\u89e6\uff1a<\/b><br class=\"dnr\" \/>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p><\/div><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>\u00a0 DALLAS,\u00a0June 26, 2025 \u2014\u00a0Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe vision loss from\u00a0retinal degenerative diseases, today announced the formation of its\u00a0Visionary Advisory Committee (VAC)\u00a0\u2013 a group of renowned experts in retina treatment and commercialization. The VAC will serve as a strategic and mission-aligned team that informs Nanoscope\u2019s scientific, clinical, and community-facing efforts.\u00a0Its mission: to elevate the care of patients, foster authentic engagement with physicians, and help chart the path to delivering a transformative therapy first to people living with retinitis pigmentosa (RP) and Stargardt disease (SD). \u201cThis is more than just a committee \u2014 it represents a clear [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":8841,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-8840","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-26T11:16:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:08:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee\",\"datePublished\":\"2025-06-26T11:16:52+00:00\",\"dateModified\":\"2025-07-13T20:08:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\"},\"wordCount\":727,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\",\"name\":\"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg\",\"datePublished\":\"2025-06-26T11:16:52+00:00\",\"dateModified\":\"2025-07-13T20:08:42+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u65b0\u305f\u306a\u5148\u898b\u6027\u306e\u3042\u308b\u8aee\u554f\u59d4\u54e1\u4f1a\u3092\u8a2d\u7acb\u3057\u3001\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u306b\u304a\u3051\u308b\u60a3\u8005\u4e2d\u5fc3\u306e\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u63a8\u9032 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-06-26T11:16:52+00:00","article_modified_time":"2025-07-13T20:08:42+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee","datePublished":"2025-06-26T11:16:52+00:00","dateModified":"2025-07-13T20:08:42+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/"},"wordCount":727,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","url":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u65b0\u305f\u306a\u5148\u898b\u6027\u306e\u3042\u308b\u8aee\u554f\u59d4\u54e1\u4f1a\u3092\u8a2d\u7acb\u3057\u3001\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u306b\u304a\u3051\u308b\u60a3\u8005\u4e2d\u5fc3\u306e\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u63a8\u9032 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg","datePublished":"2025-06-26T11:16:52+00:00","dateModified":"2025-07-13T20:08:42+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/8840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=8840"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/8840\/revisions"}],"predecessor-version":[{"id":9068,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/8840\/revisions\/9068"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/8841"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=8840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=8840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=8840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}